| Transcode Therapeutics, Inc. (RNAZ) | |||||||||||||||||||||||||||||||||||||||||||||||||
| Q2-CY2026 | Q1-CY2026 | Q4-CY2025 | Q3-CY2025 | Q2-CY2025 | Q1-CY2025 | Q4-CY2024 | Q3-CY2024 | Q2-CY2024 | Q1-CY2024 | Q4-CY2023 | Q3-CY2023 | Q2-CY2023 | Q1-CY2023 | Q4-CY2022 | Q3-CY2022 | Q2-CY2022 | Q1-CY2022 | Q4-CY2021 | Q3-CY2021 | Q2-CY2021 | Q1-CY2021 | Q4-CY2020 | Q3-CY2020 | Q2-CY2020 | Q1-CY2020 | Q4-CY2019 | Q3-CY2019 | Q2-CY2019 | Q1-CY2019 | Q4-CY2018 | Q3-CY2018 | Q2-CY2018 | Q1-CY2018 | Q4-CY2017 | Q3-CY2017 | Q2-CY2017 | Q1-CY2017 | Q4-CY2016 | Q3-CY2016 | Q2-CY2016 | Q1-CY2016 | Q4-CY2015 | Q3-CY2015 | Q2-CY2015 | Q1-CY2015 | Q4-CY2014 | Q3-CY2014 | Q2-CY2014 | |
| Balance Sheet Date | 2025-Dec-31 | 2025-Sep-30 | 2025-Jun-30 | 2025-Mar-31 | 2024-Dec-31 | 2024-Sep-30 | 2024-Jun-30 | 2024-Mar-31 | 2023-Dec-31 | 2023-Sep-30 | 2023-Jun-30 | 2023-Mar-31 | 2022-Dec-31 | 2022-Sep-30 | 2022-Jun-30 | 2022-Mar-31 | 2021-Dec-31 | 2021-Sep-30 | 2021-Jun-30 | ||||||||||||||||||||||||||||||
| Fiscal Period | Q4-FY2025 | Q3-FY2025 | Q2-FY2025 | Q1-FY2025 | Q4-FY2024 | Q3-FY2024 | Q2-FY2024 | Q1-FY2024 | Q4-FY2023 | Q3-FY2023 | Q2-FY2023 | Q1-FY2023 | Q4-FY2022 | Q3-FY2022 | Q2-FY2022 | Q1-FY2022 | Q4-FY2021 | Q3-FY2021 | Q2-FY2021 | ||||||||||||||||||||||||||||||
| Operating Cash Flow | (8,142,010$) | (4,083,173$) | (4,194,339$) | (3,096,707$) | (3,146,337$) | (3,912,615$) | (2,339,768$) | (3,937,227$) | (5,663,489$) | (3,505,794$) | (4,391,701$) | (4,513,551$) | (4,019,724$) | (4,422,028$) | (3,372,194$) | (3,948,566$) | (1,600,753$) | (3,067,980$) | (522,153$) | (255,491$) | (130,836$) | ||||||||||||||||||||||||||||
| Investing Cash Flow | (500$) | (12,870$) | (4,555$) | (3,836$) | 0$ | (4,606$) | (18,107$) | (12,896$) | (28,215$) | 0$ | (42,047$) | (30,657$) | (82,728$) | (71,551$) | (75,301$) | ||||||||||||||||||||||||||||||||||
| Purchases of Property and Equipment | 500$ | 12,870$ | 4,555$ | 3,836$ | 0$ | 4,606$ | 18,107$ | 12,896$ | 28,215$ | 0$ | 42,047$ | 30,657$ | 85,728$ | 71,551$ | 75,301$ | ||||||||||||||||||||||||||||||||||
| Financing Cash Flow | 23,124,051$ | (455,726$) | 0$ | 8,854,797$ | 7,082,039$ | 2,446,796$ | 785,198$ | 6,087,141$ | 978,153$ | 7,390,859$ | 6,359,626$ | 1,180,686$ | 225,817$ | (225,817$) | 0$ | 5,989$ | 9,485$ | 25,559,820$ | (131,600$) | (12,429$) | (61,055$) | ||||||||||||||||||||||||||||
| End Cash Position | 17,813,521$ | 2,835,916$ | 7,374,815$ | 11,569,154$ | 5,811,064$ | 1,875,862$ | 3,354,551$ | 4,913,676$ | 2,767,598$ | 7,452,934$ | 3,572,475$ | 1,622,657$ | 4,968,418$ | 8,790,540$ | 13,438,385$ | 16,852,626$ | 20,825,860$ | 22,499,856$ | 79,567$ | 98,962$ | 828,016$ | 1,095,936$ | 1,287,827$ | ||||||||||||||||||||||||||
| Exchange Rate Effect | |||||||||||||||||||||||||||||||||||||||||||||||||
| Dividends Paid | |||||||||||||||||||||||||||||||||||||||||||||||||
| Unlevered Free Cash Flow | (8,142,010$) | (4,083,173$) | (4,194,339$) | (3,096,707$) | (3,146,837$) | (3,925,485$) | (2,344,323$) | (3,941,063$) | (5,663,489$) | (3,510,400$) | (4,409,808$) | (4,526,447$) | (4,047,939$) | (4,422,028$) | (3,414,241$) | (3,979,223$) | (1,686,481$) | (3,139,531$) | (597,454$) | (255,491$) | (130,836$) | ||||||||||||||||||||||||||||